{"entity":{"id":"mytx-011","kind":"drug","name":"MYTX-011","aka":[],"tldr":"MYTX-011 is an experimental antibody-drug conjugate from Mythic Therapeutics, in phase 1 trials for non-small cell lung cancer; its current status is not stated.","summary":"MYTX-011 is an antibody-drug conjugate (cMET-targeted, MMAE payload, DAR 2) from Mythic Therapeutics. An antibody-drug conjugate targeting cMET (MET) carrying MMAE at a drug-to-antibody ratio of 2, engineered on the FateControl platform. Its furthest stage is phase 1, for non-small cell lung cancer. ClinicalTrials.gov registers it in one study linked below. KisMET-01 (NCT05652868) terminated for 'Business decision' (completion Nov 2025); Mythic made an assignment for the benefit of creditors on 21 Nov 2025 and the assets were offered for sale (bid deadline 5 Jan 2026). Buyer not known. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Mythic Therapeutics: biospace.com","url":"https://www.biospace.com/press-releases/sale-of-intellectual-property-mythic-therapeutics-inc"},{"label":"Mythic Therapeutics: biospace.com","url":"https://www.biospace.com/press-releases/sale-of-intellectual-property-mythic-therapeutics-inc"},{"label":"Mythic Therapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT05652868"},{"label":"ClinicalTrials.gov: trials of MYTX-011","url":"https://clinicaltrials.gov/search?intr=MYTX-011"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":["met"],"drugs":[],"companies":["mythic-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05652868"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"MYTX-011","modality":"Antibody-drug conjugate (cMET-targeted, MMAE payload, DAR 2)","mechanism":"An antibody-drug conjugate targeting cMET (MET) carrying MMAE at a drug-to-antibody ratio of 2, engineered on the FateControl platform.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/mytx-011/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"target":[{"id":"met","kind":"target","name":"MET","route":"/targets/met/"}],"company":[{"id":"mythic-therapeutics","kind":"company","name":"Mythic Therapeutics","route":"/companies/mythic-therapeutics/"}],"trial":[{"id":"nct05652868","kind":"trial","name":"Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer","route":"/trials/nct05652868/"}]}}